ArticleExperimental hematology & oncology2019
Article in Experimental hematology & oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Regulatory Variants in the KRAS 3'UTR and Intron 2 Are Associated with Breast Cancer Susceptibility Through Independent and Combinatorial Effects in a Mexican Population.Biomedicines · 2026Article
- Congenital hepatoblastoma presenting with hepatic arteriovenous fistulas: a case report.Frontiers in pediatrics · 2023Article
- METTL1 gene polymorphisms synergistically confer hepatoblastoma susceptibility.Discover oncology · 2022Article
- Article
- Article
- The Curious Case of the HepG2 Cell Line: 40 Years of Expertise.International journal of molecular sciences · 2021Review
- Article
- KRAS gene polymorphisms are associated with the risk of glioma: a two-center case-control study.Translational pediatrics · 2021Article
- The Genetic Changes of Hepatoblastoma.Frontiers in oncology · 2021Review
- Association between lncRNA-H19 polymorphisms and hepatoblastoma risk in an ethic Chinese population.Journal of cellular and molecular medicine · 2021Article
- No Association BetweenPharmacogenomics and personalized medicine · 2021Article
- Article
- Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatoblastoma is the most common hepatic malignancy in children, accounting for approximately 80% of all childhood liver tumors.
methodsWe investigated whether the polymorphisms at these genes are associated with hepatoblastoma susceptibility in a hospital-based study of 213 affected Chinese children and 958 cancer-free controls. Genotypes were determined by TaqMan assay, and association with hepatoblastoma risk was assessed based on odds ratios and 95% confidence intervals.
resultsNo significant differences were observed between patients and controls in terms of age and gender frequency. All
conclusionsThe data suggest that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.